Morgan Stanley analyst Judah Frommer downgraded Mural Oncology (NASDAQ: MURA) from Overweight to Equalweight.The analyst comments "We remove the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE